Abstract
Drug delivery across the blood-brain barrier (BBB) remains a significant challenge in the treatment of neurological disorders. Recent advancements in drug delivery systems (DDS) have shown promising potential in overcoming the BBB's selective permeability, enhancing the bioavailability of therapeutic agents in the brain. This article reviews the latest developments in DDS technologies such as nanoparticles, liposomes, and carrier-mediated transport systems, and evaluates their effectiveness in targeting the central nervous system (CNS). The article also discusses the current challenges, safety considerations, and future prospects for integrating DDS into clinical neurology.
All articles published in the American Journal of Pharmacy and Pharmacology are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows others to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given to the original author(s) and source, a link to the license must be provided, and any changes made must be indicated.
By submitting their work, authors agree to these licensing terms and retain copyright of their articles.